Ernestina Santos1, Ester Coutinho2, Ana Martins da Silva3, António Marinho4, Carlos Vasconcelos5, Ricardo Taipa6, Manuel Melo Pires7, Guilherme Gonçalves8, Carlos Lopes9, Maria Isabel Leite10. 1. Neurology Department, Hospital Santo António, Centro Hospitalar Porto, Porto, Portugal; Multidisciplinary Unit for Biomedical Research (UMIB), Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Portugal. Electronic address: ernestina.santos@gmail.com. 2. Nuffield Department of Clinical Neurosciences, Oxford University Hospitals and University of Oxford, Oxford, United Kingdom. Electronic address: estercoutinho@gmail.com. 3. Neurology Department, Hospital Santo António, Centro Hospitalar Porto, Porto, Portugal; Multidisciplinary Unit for Biomedical Research (UMIB), Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Portugal. Electronic address: anaadmsilva@gmail.com. 4. Clinical Immunology Unit, Hospital Santo António, Centro Hospitalar Porto, Porto, Portugal. Electronic address: antmarinho@hotmail.com. 5. Clinical Immunology Unit, Hospital Santo António, Centro Hospitalar Porto, Porto, Portugal. Electronic address: cvcarlosvasconcelos@gmail.com. 6. Neuropathology Unit, Hospital Santo António, Centro Hospitalar Porto, Porto, Portugal. Electronic address: ricardotaipa@gmail.com. 7. Neuropathology Unit, Hospital Santo António, Centro Hospitalar Porto, Porto, Portugal. Electronic address: melopires@hotmail.com. 8. Multidisciplinary Unit for Biomedical Research (UMIB), Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Portugal. Electronic address: aggoncalves@icbas.up.pt. 9. Pathology and Molecular Immunology Department, Instituto de Ciências Biomédicas de Abel Salazar, Universidade do Porto, Porto, Portugal. Electronic address: lopes81241@gmail.com. 10. Nuffield Department of Clinical Neurosciences, Oxford University Hospitals and University of Oxford, Oxford, United Kingdom. Electronic address: maria.leite@ndcn.ox.ac.uk.
Abstract
INTRODUCTION: The association of myasthenia gravis (MG) and inflammatory myopathy is rare and often only one of the diseases is diagnosed. Thymus pathology may be in the origin of such disease association. METHODS: We described four patients with both MG and inflammatory myopathy. RESULTS: These cases correspond to 2.3% of our MG cohort. Case 1: MG, polymyositis and thymolipoma; case 2: MG and necrotizing myopathy without thymic pathology on a background of scleroderma, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, telangiectasia (CREST); case 3: MG and dermatomyositis without thymic pathology; case 4: MG and dermatomyositis with type C thymoma. DISCUSSION: The recognition of these neuromuscular co-morbidities contributes to (i) understanding their pathogenic mechanisms, (ii) developing better management approaches and (iii) further improving disease outcomes.
INTRODUCTION: The association of myasthenia gravis (MG) and inflammatory myopathy is rare and often only one of the diseases is diagnosed. Thymus pathology may be in the origin of such disease association. METHODS: We described four patients with both MG and inflammatory myopathy. RESULTS: These cases correspond to 2.3% of our MG cohort. Case 1: MG, polymyositis and thymolipoma; case 2: MG and necrotizing myopathy without thymic pathology on a background of scleroderma, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, telangiectasia (CREST); case 3: MG and dermatomyositis without thymic pathology; case 4: MG and dermatomyositis with type C thymoma. DISCUSSION: The recognition of these neuromuscular co-morbidities contributes to (i) understanding their pathogenic mechanisms, (ii) developing better management approaches and (iii) further improving disease outcomes.
Authors: Zeead M Alghamdi; Sharifah A Othman; Mohammed Sabry Abdelmotaleb; Farouk Alreshaid; Abdullah Alomar; Mohammed Alaklbi; Hatem Y Elbawab; Yasser Aljehani Journal: Interact Cardiovasc Thorac Surg Date: 2022-03-31